PMC:7283670 / 67382-67888
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T234 | 437-441 | Body_part | denotes | body | http://purl.org/sig/ont/fma/fma256135 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T379 | 45-53 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T380 | 80-88 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T599 | 99-101 | http://purl.obolibrary.org/obo/CLO_0050510 | denotes | 18 |
| T600 | 227-228 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T218 | 0-11 | Chemical | denotes | Tetrandrine | http://purl.obolibrary.org/obo/CHEBI_49 |
| T219 | 201-212 | Chemical | denotes | Tetrandrine | http://purl.obolibrary.org/obo/CHEBI_49 |
| T220 | 219-221 | Chemical | denotes | QD | http://purl.obolibrary.org/obo/CHEBI_50853 |
| T221 | 378-380 | Chemical | denotes | IV | http://purl.obolibrary.org/obo/CHEBI_74327 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T658 | 0-281 | Sentence | denotes | Tetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day) |
| T659 | 282-506 | Sentence | denotes | No intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020 |